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Background: MicroRNAs (miRNAs) are involved in numerous biological and pathological processes including
colorectal cancer (CRC). The aim of our study was to evaluate the ability of miRNA expression patterns to predict
chemotherapy response in a cohort of 78 patients with metastatic CRC (mCRC).
Methods: We examined expression levels of 667 miRNAs in the training cohort and evaluated their potential
association with relevant clinical endpoints. We identified a miRNA profile that was analysed by RT-qPCR in an
independent cohort. For a set of selected miRNAs, bioinformatic target predictions and pathway analysis were
also performed.
Results: Eight miRNAs (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p)
were significant predictors of response to chemotherapy in the training cohort. In addition, overexpression of
miR-107, miR-337-5p and miR-99a-3p, and underexpression of miR-889, were also significantly associated with
improved progression-free and/or overall survival. MicroRNA-107 and miR-99a-3p were further validated in an
independent cohort as predictive markers for chemotherapy response. In addition, an inverse correlation was
confirmed in our study population between miR-107 levels and mRNA expression of several potential target
genes (CCND1, DICER1, DROSHA and NFKB1).
Conclusions: MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based
chemotherapy in patients with mCRC.
Keywords: MicroRNAs, Advanced colorectal cancer, Chemotherapy response, PredictionBackground
Colorectal cancer (CRC) is one of the most common
malignant tumors worldwide [1]. Despite advances in early
detection, about one third of patients present metastatic
disease at diagnosis, and ~40% of those with early-stage
tumors eventually relapse at some point over the course
of the disease [2]. Systemic therapy is the mainstay of care* Correspondence: rgcarbonero@gmail.com
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article, unless otherwise stated.for patients with metastatic CRC (mCRC) [3]. Several
combination regimens including fluoropyrimidines and
oxaliplatin and/or irinotecan, with or without monoclonal
antibodies targeting VEGF or EGFR, have been success-
fully developed and are associated with response rates of
40-60% and a median survival of 20–24 months [4-9].
Despite the undeniable progress achieved, still a consider-
able proportion of patients do not respond to therapy and
reliable tools to prospectively identify which patients are
more likely to benefit are needed.
Several driver mutations have been identified to be
relevant in CRC carcinogenesis [10,11]. The most com-
monly involved pathways include the Wnt/β-catenin,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this





Age, years – median [range] 62 [54–70] 66 [61–72]
Gender - N(%)
Male 23 (59.0%) 29 (74.4%)
Female 16 (41.0%) 10 (25.6%)
Histology of primary
tumor - N(%)
Adenocarcinoma 35 (89.7%) 39 (100%)
Mucinous adenocarcinoma 4 (10.3%) -
Chemotherapy regimen - N(%)
Ox/FP regimens 30 (76.9%) 29 (74.3%)
Ir/FP regimens 7 (17.9%) 9 (23.1%)
FP monotherapy 2 (5.2%) 1 (2.6%)
Response to
chemotherapy - N(%)
Objective Response (CR, PR) 18 (46.2%) 24 (61.5%)
No Response (SD, PD) 21 (53.8%) 15 (38.5%)
Survival, months – median
[range]
Progression-free survival 12.2 [6.3-18.9] 11.6 [8.6-18.3]
Overall survival 24.6 [15.8-37.2] 21.5 [13.3-31.1]
Continuous variables are expressed as median [interquartile range (IQR)] and
categorical variables as number of cases (%). Ox: oxaliplatin; FP:
fluoropyrimidine; Ir: Irinotecan. CR: complete response; PR: partial response;
SD: stable disease; PD: progressive disease.
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PI3K signaling pathways [10]. Many of these proteins are
altered and seem to be affected by microRNA regulation.
In this sense, the miR-135 family may play an important
role in early CRC development as it down-regulates APC,
leading to activation of the Wnt/β-catenin pathway [12].
On the other hand, the lethal-7 (let-7) family of miRNAs
has been found to display tumor suppressor functions by
repressing translation of KRAS. Interestingly, patients
with KRAS-mutated CRC and high let-7 levels seem to
benefit from EGFR-targeted agents, suggesting that let-7
expression could potentially counteract resistance medi-
ated by RAS activating mutations [13]. KRAS has been
also described to be a direct target of other miRNAs such
as miR-143, miR-146b-3p, miR-18a, and miR-486-5p
[14-17] and miR-126 has been implicated in PI3K signal-
ling [18]. Other miRNAs known to be involved in CRC
pathogenesis affect epithelial differentiation (miR-141 and
miR-200c), WNT signaling (miR-145, miR-135a and miR-
135b), and migration and invasion (miR-21, miR-373 and
miR-520c) [19-22].
From a clinical perspective, several studies have identi-
fied groups of miRNAs with potential utility for early
diagnosis or prognostic stratification of CRC patients.
However, there are no robust studies to evaluate the po-
tential ability of miRNA to predict response to selected
chemotherapy regimens. Based on these premises, the
purpose of this study was to evaluate the ability of miRNA
expression patterns to predict chemotherapy response in
patients with mCRC treated with fluoropyrimidine-based
standard chemotherapy regimens.
Methods
Patients and tumor samples
Patients that met the following inclusion criteria were
selected for the present study: (1) histologically con-
firmed diagnosis of primary CRC; (2) TNM stage IV; (3)
fluoropyrimidine-based first-line chemotherapy for ad-
vanced disease; (4) measurable disease per RECIST cri-
teria; (5) adequate clinical data recorded in medical
charts; (6) adequate tissue specimen available (snap-
frozen at −80°C with a proportion of tumor cells > 50%).
This study was approved by the ethics committees of
Hospital Universitario Virgen del Rocio (Sevilla), Hos-
pital Marques de Valdecilla (Santander) and Hospital
Virgen de la Victoria (Malaga), and all patients provided
written informed consent prior to study entry.
Tumor tissue samples of 78 patients were collected at
the Hospital Universitario Virgen del Rocio (Sevilla), Hos-
pital Marques de Valdecilla (Santander), Hospital Virgen
de la Victoria (Malaga) and Hospital de la Merced (Osuna).
Main characteristics of study population are summarized
in Table 1 and are representative of a standard metastatic
CRC population. The majority of patients (96%) weretreated with a chemotherapy regimen that included fluoro-
pyrimidines and either oxaliplatin (76%) or irinotecan
(20%). The patient population was divided in a training
cohort (N = 39) that was used for miRNA profile develop-
ment and an independent validation cohort (N = 39).
Clinical outcome variables and statistical analysis
Descriptive statistics were used to characterize the most
relevant clinical parameters. The association of categor-
ical variables was explored by the chi-squared test or
Fisher’s exact test. To assess distribution of continuous
variables among study groups parametric (t-test) or non-
parametric tests (Kruskal-Wallis or Mann–Whitney tests)
were employed when appropriate.
Tumor response was evaluated by conventional methods
according to the standard RECIST 1.0 criteria: a complete
response (CR) was defined as the disappearance of all
measurable and evaluable evidence of disease; a partial re-
sponse (PR) was defined as a ≥ 30% decrease in the sum of
the longest diameters of target lesions; stable disease (SD)
was considered if the tumor burden decreased less than
30% or increased less than 20%; and progressive disease
(PD) was indicated by a >20% increase in the sum of the
longest diameters of target lesions or the appearance of
any new lesion. Patients were classified according to
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that achieved an objective response (Responders [R]:
CR + PR) and those that did not (Non-responders [NR]:
SD + PD). Progression Free Survival (PFS) was defined
as the time elapsed from the date of initiation of first-
line chemotherapy to the date of the first documented
evidence of disease progression. Overall survival (OS)
was calculated from the start of therapy for advanced
disease to the date of death from any cause. The Kaplan-
Meier product limit method was used to estimate
time-dependent variables (PFS and OS), and differences
observed among patient subgroups were assessed by the
log rank test. Multivariate analyses were performed using
the Cox proportional hazards model. P < 0.05 was consid-
ered significant. All analyses were performed using the
Statistical Package for the Social Sciences software (SPSS
17.0 for Windows; SPSS Inc, Chicago, IL).
RNA isolation and miRNA qRT-PCR assay
Total RNA, containing small RNA, was extracted from
tumor tissue samples by mirVana miRNA isolation kit
(Ambion, Austin, TX, USA) according to the manufac-
turer’s instructions. Mature human miRNA expression
was detected and quantified using the TaqMan® Low
Density Arrays (TLDA) based on Applied Biosystems’
7900 HT Micro Fluidic Cards (Applied Biosystems, CA,
USA) following instructions provided by the manufac-
turer. The Human MicroRNA Card Set v2.0 array is a
two card set containing a total of 384 TaqMan® Micro-
RNA Assays per card to enable accurate quantification
of 667 human microRNAs, all catalogued in the miR-
Base database. TLDAs were performed in a two-step
process, as previously described [23].
Eight miRNAs (let-7 g*, miR-107, miR-299-5p, miR-
337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p),
which were selected because their expression in the Taqman
Low Density Array card assays was significantly associated
with response to chemotherapy and clinical outcome, were
further analyzed in an independent validation cohort by
qPCR. For this, RNA was reverse transcribed to cDNA
using TaqMan® MicroRNA Assays (Applied Biosystems,
CA, USA). Ten ng of total RNA were reverse transcribed
using the TaqMan miRNA reverse transcription kit in a total
volume of 15 μl, according to the manufacturer's protocol.
The reactions were incubated for 30 min at 16°C, 30 min at
42°C, and 5 min at 85°C, and then kept at 4°C. Thereafter,
1.33 μL of cDNA was used for TaqMan MicroRNA Assays.
The reactions were incubated at 95°C for 10 min, followed
by 40 cycles of 15 sec at 95°C and 1 min at 60°C. All experi-
ments were performed in triplicate.
Analysis of miRNA expression profiles
Expression of target miRNAs was normalized to the ex-
pression of MammU6, the most widely-used endogenousmiRNA control for RT-qPCR in the literature. One
non-human miRNA was used in each experiment as a
negative control. Finally, the cards were processed and
analyzed on an ABIPrism 7900 HT Sequence Detection
System. Cycle threshold (Ct) values were calculated with
the SDS software v.2.3 using automatic baseline settings
and a threshold of 0.2. Relative quantification of miRNA
expression was calculated by the 2−ΔΔCt method (Ap-
plied Biosystems user bulletin no.2 (P/N 4303859)).
MicroRNAs expression was computed using Real-Time
Statminer© software v.4.2 (Integromics, Inc). This soft-
ware performs a moderate t-test between the groups
(R versus NR) and corrects them using the Benjamini-
Hochberg algorithm with the False Discovery Rate (FDR) set
at a value of 5%. For undetected miRNAs with Ct values be-
yond the maximum Ct 36, the StatMiner software imputed
a value set to the maximum Ct. For the purpose of this
study, significant miRNA expression was considered only
when miRNAs were detected in at least 50% of samples in
each group being compared. The raw and normalized Taq-
Man array data have been deposited in the Gene Expression
Omnibus under the accession number GSE48664.
Experimentally verified mRNA by previous research were
determined using the web-accessible information resource
miRWalk [24]. We then validated 9 potential target genes
according to expression levels of mir-107 by Taqman real-
time RT-PCR assay (Applied Biosystems, CA, USA). Ex-
pression of miR-107 was normalized to the expression of
MammU6. Pearson's correlation coefficient was used to
assess the linear association of miRNA and target mRNA
expression (SPSS 17.0 for Windows; SPSS Inc, Chicago, IL).
3′-UTR reporter assay for miR target validation
Confirmation of miR-107-binding to the 3′-UTR of CCDN1.
HEK 293 cells at 80% confluency were co-transfected with
luciferase reporter plasmids harboring the complete 3′-UTR
of the desired gene (SwitchGear Genomics) along with
100nM of miR107-mimic or miRNA control (Sigma).
DharmaFECT Duo (Thermo Scientific) was used as the
transfection reagent in Opti-MEM (Life Technologies).
Luminescence was assayed 24 hours later using Light-
Switch Assay Reagents (SwitchGear Genomics) accord-
ing to the manufacturer's instructions. Knockdown
was assessed by calculating luciferase signal ratios for
specific miRNA/non-targeting control, using empty
reporter vector as control for non-specific effects. Each
experiment was performed in triplicate
Results
MicroRNA profile development
MicroRNA expression patterns according to objective
response to chemotherapy
The relative miRNA expression levels for patients that
achieved an objective response to chemotherapy (R) versus
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Figure S1. Of the 667 miRNAs assessed, 7% (N= 46) were
differentially expressed (p < 0.05) among these two sub-
groups described (R versus NR). However, only eight of
these 46 miRNAs were detected in at least 50% of tested
samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p,
miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2),
and were therefore considered to be representative of the
general behaviour of the study population.
Impact of selected miRNAs expression on progression free
and overall survival
These selected miRNAs able to predict response to
chemotherapy were further assessed to evaluate their
potential association with progression free survival (PFS)
and overall survival (OS) of patients. Overall, median
PFS was 13.6 months [range: 8.8-21.2] and median OS
was 25.6 months [range: 17.1-39.3], consistent with sur-
vival data reported in the literature for this patient popula-
tion. Kaplan-Meier estimates for PFS and OS according to
miRNA expression levels grouped as above or below the
median are shown in Figure 1A and B, respectively. Among
tested miRNAs, expression of miR-107, miR-337-5p and
miR-99a-3p was significantly associated with both PFS and
OS (p < 0.05), while that of miR-889 was only associated
with OS (p < 0.05). In addition, a trend of borderline
significance was observed for miR-370 with OS (p = 0.094).
Multivariate analyses confirmed miR-107, miR-337-5p
and miR-99a-3p as independent predictive factors for PFS.
Regarding overall survival, only miR-889, together with
age and sex retained independent prognostic significance
in the Cox multiple regression model (Table 3).
Independent validation
As depicted in Figure 2, miRNA expression patterns in
this validation cohort were consistent with those quanti-
fied in the training cohort, in the sense that similarTable 2 Differently expressed miRNAs by objective
response to chemotherapy (Training Cohort)
MicroRNAs R vs NR (−ΔΔCt) Adjusted p-values*








R – responders to chemotherapy (complete or partial response); NR – non-responders
to chemotherapy (stable or progressive disease) (RECIST criteria).
*p values adjusted for multiple testing by Benjamini-Hochberg method. The
bold value indicates a statistically significant result.association trends were observed between over- or
under-expression of miRNAs and response to therapy.
However, this association only achieved statistical sig-
nificance for miR-107 and miR-99a-3p, with higher ex-
pression levels in mCRC patients that achieved an objective
response to chemotherapy as compared to those that did
not (p = 0.026 and p = 0.027, respectively).
MicroRNA target prediction
A bioinformatic approach was used to identify experimen-
tally verified target mRNAs of the validated miRNAs in
our series, miR-107 and miR-99a-3p. However, whereas a
number of genes have been experimentally validated to
date for miR-107, none were identified for miR-99a-3p.
Among the former, 9 of the miR-107 potential target
genes were selected for further validation in our cohort,
including genes involved in the PI3K/Akt signaling path-
way and in the RNA-interference processing machinery.
MicroRNA-107 target genes assessed were AKT1 (v-akt
murine thymoma viral oncogene homolog 1), CCND1
(cyclin D1), COX8A (cytochrome c oxidase subunit
VIIIA), DICER1 (dicer 1, ribonuclease type III), DROSHA
(drosha, ribonuclease type III), FASN (fatty acid synthase),
FBXW7 (F-box and WD repeat domain containing 7),
NFKB1 (nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1), and TP53 (tumor protein p53). As
depicted in Figure 3, an inverse correlation was observed
between these nine mRNAs and miR-107 expression
levels, being this correlation significant for CCND1,
DICER1, DROSHA and NFKB1. Therefore, in individual
tumor samples, higher levels of miR-107 were associated
with lower levels of these targets. Subsequently, CCDN1
target was quantified using luciferase reporter gene assays.
We observed that overexpression of miR-107 in HEK 293
cells significantly down-regulated the luciferase activity
of reporter construct containing the CCDN1 3′-UTR
(Figure 4). This data indicate that miR-107 binds directly
to this target RNA and inhibits its expression, further
supporting a potential role for miR-107 in the regulation
of these genes.
Discussion
In this study, we have evaluated global miRNA expression
patterns in mCRC patients treated with fluoropyrimidine-
based standard chemotherapy regimens. We identified
eight miRNAs (let-7 g*, miR-107, miR-299-5p, miR-337-
5p, miR-370, miR-505*, miR-889 and miR-99a-3p), the
expression of which was significantly associated with
response to chemotherapy. In addition, overexpression
of miR-107, miR-337-5p and miR-99a-3p, and underex-
pression of miR-889, were also significantly associated
with improved progression-free and/or overall survival.
Moreover, miR-107 and miR-99a-3p were further vali-
dated in an independent cohort as predictive markers
Figure 1 Training cohort: Clinical outcome of patients by miRNA expression levels. (A) Progression-free survival (PFS) and (B) Overall survival.
The solid red line represents patients with higher miRNA expression levels (above the median). The solid green line represents patients with lower
miRNA expression levels.
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Figure 2 Validation cohort: Median ΔCt values of validated miRNAs in patients with objective response to chemotherapy responders
versus non-responders. *p-value < 0.05. Data derived from RT-qPCR are presented as ΔCt values, with higher values standing for lower
miRNA-expression. R: Responders; NR: Non-Responders.
Table 3 Univariate and multivariate analysis of predictive miRNA for PFS and OS in metastatic colorectal cancer
patients (Training Cohort)
VARIABLES PFS OS
Univariate Analysis Multivariate Analysis Univariate Analysis Mutivariate Analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age 0.99 [0.95-1.02] 0.357 0.99 [0.95-1.04] 0.765 1.01 [0.96-1.05] 0.746 1.06 [1.01-1.12] 0.027
Sex 0.51 [0.24-1.07] 0.069 0.60 [0.26-1.40] 0.232 0.42 [0.16-1.10] 0.069 0.17 [0.05-0.54] 0.003
miR-107 2.12 [1.05-4.29] 0.043 2.52 [1.18-5.42] 0.017 2.65 [1.06-6.67] 0.035 2.61 [0.86-7.92] 0.091
miR-337-5p 2.27 [1.12-4.58] 0.018 3.02 [1.34-6.83] 0.008 2.53 [0.95-6.80] 0.018 1.40 [0.42-4.69] 0.584
miR-99a-3p 2.34 [1.11-4.93] 0.030 2.50 [1.00-6.05] 0.050 3.46 [1.26-9.53] 0.008 1.99 [0.62-6.36] 0.243
miR-889 0.45 [0.22-0.94] 0.073 0.40 [0.16-0.90] 0.027 0.26 [0.10-0.71] 0.017 0.15 [0.04-0.47] 0.001
PFS: progression free survival; OS: overall survival; CI: confidence interval; HR: Hazard Ratio.
The bold value indicates a statistically significant result.
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Figure 3 Negative correlation between several potential target genes and miR-107 expression.
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the first study to assess the predictive role of miRNA
expression profiles in patients with advanced CRC treated
with fluoropyrimidines in combination with either oxali-
platin (77%) or irinotecan (18%), the most commonly used
chemotherapy regimens in the treatment of this
disease.
Altered miR-107 expression has been involved in several
cancer types, including head and neck squamous cell car-
cinoma (HNSCC), ovarian, gastric or breast cancer, among
others [25-27]. Our results have demonstrated that expres-
sion of this miRNA significantly influences sensitivity to
fluoropyrimidine-based chemotherapy in patients withadvanced colorectal cancer. miR-107 transcription is
induced by p53 and it seems to function as a tumor
suppressor gene in HNSCC cell lines through downreg-
ulation of protein kinase Cε (PKCε) [25]. PKCε is ele-
vated in HNSCC and has been associated with a more
aggressive phenotype [28]. Consistent with this, other
groups have reported a tumor suppressor function for
miR-107 in other cancer models including bladder, colon
and pancreatic cancer. With regard to human colon can-
cer, miR-107 has been shown to regulate tumor angiogen-
esis by targeting hypoxia inducible factor-1β (HIF-1β)
[29]. Indeed, overexpression of miR-107 in HCT116 colon
cancer cells suppressed angiogenesis, tumor growth and
Figure 4 3′-UTR reporter assay for miR target validation. HEK
293 cells were transfected with luciferase reporter vector
containing the 3′-UTR region of CCDN1. Reporter vectors were
co-transfected with a miR-107 mimic or control miRNA mimic (miR NC).
Following 24 h incubation, luciferase activity was measured.
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genesis induced by miR-107 may make tumor cells more
vulnerable to a variety of cellular insults including geno-
toxic stress induced by DNA-damaging agents (i.e. conven-
tional cytotoxic chemotherapy). In fact, antiangiogenic drugs
such as the VEGF-targeting agents bevacizumab or afliber-
cept have demonstrated to be synergistic in combination
with fluoropyrimidine-based chemotherapy in patients
with advanced colorectal cancer. Moreover, other authors
have shown that, compared with wild type tumors, tumors
that lack HIF-1α are poorly vascularized but are faster
growing, perhaps because of a loss of dependency upon
neovascularization. These findings would be consistent
with the increased response rate and improved prognosis
observed in our series for patients over-expressing miR-
107 [30,31]. In addition, overexpression of miR-107 has
been recently shown in gastric cancers in comparison with
normal tissue, and up-regulation of these miRNA in-
creased the proliferation of gastric cancer cells [32]. In
colon cancer models some authors have reported that
miR-103/107 may promote metastasis by targeting the
metastasis suppressors DAPK and KLF4 [33]. They also
found that, in the clinical setting, the signature of a miR-
103/107 high, DPAK and KLF4 low expression profile
correlated with the extent of lymph node and distant me-
tastasis. However, no information was provided this study
regarding relevant characteristics of the patient population
such as stage of disease or therapeutic interventions. The
discrepancies observed related to miR-103/107 func-
tion could be attributed to tissue- or context–specific
effects, or may simply reflect the great complexity
governing intra- and inter-cellular signaling networks.
On the other hand, the precise role in cancer of the
other validated miRNA in our series, miR-99a-3p,
remain greatly unknown to date.
To explore the potential biological function of miR-107,
we then identified validated targets using the computa-
tional prediction algorithm from miRWalk [24]. AKT1,
CCND1, DICER1, DROSHA, FASN, FBXW7, NFKB1 andTP53 are involved in several key pathways relevant to
cancer such as the PI3K/Akt pathway and the miRNA-
processing machinery [34-39]. As expected, we confirmed
in individual tumor samples of our patients an inverse
correlation of these target mRNA and miR-107 expression
levels, being this correlation significant for CCND1, DICER1,
DROSHA and NFKB1. These results may be considered a
further validation of the functional role of miR-107 in the
transcriptional regulation of these key genes in cancer.
Conclusions
Our study has identified that miR-107 and miR-99a-3p
may be used to predict response to therapy with stand-
ard fluoropyrimidine-based chemotherapy regimens in
patients with mCRC. These results underline the great
potential of miRNAs as novel biomarkers for personal-
ized treatment strategies and also as potential thera-
peutic targets. Moreover, given the fact that CRC cells
may release aberrantly expressed miRNAs into periph-
eral blood, miRNA profiling could also have a great
potential as a minimally-invasive tool for prediction or
monitoring of therapeutic outcome.
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Additional file 1: Figure S1. Volcano plot of differentially expressed
miRNAs among responders versus non-responders to chemotherapy. The
log2 of fold change is represented on the x-axis and the negative log of
p-values from the t-test is represented on the y-axis. Dots above the dashed
line have a p-value < 0.05 and points below that line have a p-value > 0.05.
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